Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

June 30, 2008

Study Completion Date

May 31, 2010

Conditions
Ulcerative Colitis
Interventions
DRUG

AVONEX

30µg IM every week for 12 weeks

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00048347 - Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis | Biotech Hunter | Biotech Hunter